Tag Archives: UC

November, 2018

October, 2018

July, 2018

May, 2018

December, 2017

  • 14 December

    FDA Extends Action Date for Xeljanz sNDA in Ulcerative Colitis

    NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), an oral treatment under investigation for adult patients with moderately to severely active ulcerative colitis (UC). The …

September, 2017